Sotio terminates three trials studying its IL-15 superagonist due to ‘insufficient efficacy’

Czech biotech So­tio is im­me­di­ate­ly scrap­ping three clin­i­cal tri­als of its in­ter­leukin-15 su­per­ag­o­nist called nan­rilke­fusp al­fa af­ter in­ter­im da­ta showed “in­suf­fi­cient ef­fi­ca­cy.”

“While we are dis­ap­point­ed with this out­come, we will con­tin­ue to gath­er and an­a­lyze the full body of da­ta from these stud­ies to in­form our fu­ture de­vel­op­ment plans for nan­rilke­fusp al­fa,” So­tio chief med­ical of­fi­cer Richard Sachse said in a press re­lease.

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.